Vocodia Holdings Corp. Announces Engagement of Alpine Securities Corporation as Investment Banker
BOCA RATON, Fla., March 19, 2025 (GLOBE NEWSWIRE) -- Vocodia Holdings Corp. (OTC: VHAI) ('Vocodia'), a leader in AI software development focusing on practical AI applications, is pleased to announce the engagement of Alpine Securities Corporation ('Alpine') as its new investment banker. This strategic partnership aims to enhance Vocodia's financial strategies and support its continued growth in the AI industry.
Alpine Securities Corporation is a broker-dealer and boutique investment firm known for its expertise in providing tailored financial solutions to emerging companies. Their commitment to understanding the unique needs of their clients aligns with Vocodia's innovative approach to AI technology
Brian Podolak, CEO of Vocodia, commented on the engagement: 'Partnering with Alpine Securities Corporation represents a significant step forward in our mission to revolutionize the AI landscape. Their deep industry knowledge and personalized approach to investment banking will be invaluable as we continue to expand our offerings and reach new markets.'
This engagement underscores Vocodia's commitment to leveraging strategic partnerships to drive growth and innovation in the AI sector. The company looks forward to a fruitful collaboration with Alpine Securities Corporation
About Vocodia Holdings Corp.
Vocodia is an AI software company that develops practical AI solutions, making them easily accessible for businesses through cloud-based platforms. These solutions are cost-effective and scalable to enterprise levels. Vocodia specializes in conversational AI, providing scalable enterprise-level AI sales and customer service solutions. Their Digital Intelligent Sales Agents (DISAs) are designed to sound and feel human, performing tasks that require human-like conversation, thereby reducing labor costs and enhancing communication effectiveness. For more information, please visit: http://www.vocodia.com
About Alpine Securities Corporation
Alpine Securities Corporation is a broker-dealer and boutique investment firm offering a range of financial services, including investment banking, brokerage, and advisory services. With a focus on personalized client solutions, Alpine is committed to supporting the growth and success of emerging companies across various industries.
Forward-Looking Statements
This release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'believe,' 'project,' 'estimate,' 'expect,' strategy,' 'future,' 'likely,' 'may,', 'should,' 'will' and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risks and uncertainties more fully in the section captioned 'Risk Factors' in the Company's Registration Statement on Form S-1 related to the public offering (SEC File No. File No. 333-269489) and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, our actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date and undertake no duty to update such information except as required under applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
BNP Paribas Exane dubs Goodyear "tariff winner," shares surge
-- Shares of Goodyear Tire & Rubber Co (NASDAQ:GT) soared 10.7% on Monday following an upgrade by BNP Paribas (OTC:BNPQY) Exane, which dubbed the company a "true tariff winner" and heightened the price target. Analyst James Picariello elevated the stock to Outperform from Neutral, highlighting Goodyear's estimated 10.5 percentage points cost advantage in the U.S. due to tariffs and its potential for price/mix-led earnings growth. Picariello's report indicated that Goodyear's cost advantage stems from the current Section 232 auto tariffs, which levy a 25% duty rate on about 55% of all U.S. tires sold that are non-USMCA-compliant. As Goodyear is the largest tire producer in North America and only 12% of its U.S. sales are subject to these tariffs, the company enjoys a significant cost benefit. The analyst expressed confidence in Goodyear's ability to leverage this advantage for earnings upside, emphasizing the industry's need to price for tariffs. The report also noted Goodyear's progress in narrowing its margin gap compared to peers and reducing net leverage, which is expected to reach healthy levels by next year. The success of the 'Goodyear Forward' cost savings initiative, which is on track to achieve more than $1.5 billion by the first half of 2026, and the company's effective divestitures are contributing to this positive outlook. In light of these developments, BNP Paribas Exane has raised its estimates for Goodyear's EBIT and EPS for 2026-2027, with the new price target set at $15, up from the previous $11. This valuation is based on an unchanged multiple of approximately 4.4 times the estimated 2026 EV/EBITDA, compared to peers at 4.9 times, reflecting Goodyear's net leverage and profitability. The upgrade and raised price target reflect a bullish sentiment on Goodyear's strategic positioning and its ability to capitalize on market conditions, which appears to resonate with investors as evidenced by the stock's significant rise in the trading session. Related articles BNP Paribas Exane dubs Goodyear "tariff winner," shares surge FTSE 100 today: Index edges lower, U.S.-China talks in focus; Alphawave soars Wolfe Research downgrades Equinix on valuation concerns after strong rally Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Viemed Healthcare Announces Share Repurchase Program
LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the 'Company' or 'Viemed') (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ('the Common Shares') from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025. The Company intends to repurchase Common Shares through open market purchases, block purchases or otherwise in accordance with applicable securities laws. Subject to certain exceptions for block purchases, daily purchases will be limited to 25% of the average daily volume for the four calendar weeks preceding the date of purchase. Casey Hoyt, Viemed's Chief Executive Officer, noted, 'Our recent first quarter 2025 results and the increases in our 2025 guidance range midpoints demonstrate that we are executing well with strong underlying fundamentals in the business. We have a track record of disciplined capital allocation, with our latest example being the attractive acquisition of Lehan's Medical that is expected to close in the third quarter of this year. Since our public listing, we have repurchased approximately 2.6 million shares, underscoring our commitment to executing on our capital allocation strategies. With no net debt and full availability on our $55 million credit facility, we have ample liquidity to improve shareholder value with a new share repurchase program while also funding our organic and inorganic growth initiatives.' The price paid for the Common Shares will be the market price at the time of purchase, plus applicable brokerage fees, or such other prices as may be permitted by applicable securities laws. There can be no assurance as to the precise number of Common Shares that will be repurchased under the program, if any. The Company may discontinue its purchases at any time, subject to compliance with applicable securities laws. The Common Shares purchased by the Company will be cancelled. ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at statements contained in this press release may constitute 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or 'forward-looking information' as such term is defined in applicable Canadian securities legislation (collectively, 'forward-looking statements'). Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'potential', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', 'believes', 'projects', or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results 'will', 'should', 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved' or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations regarding the amount and timing of any potential repurchases of Common Shares, the funding sources for such repurchases, the availability of Common Shares for such repurchases, and the anticipated benefits to shareholders of such repurchases, as well as about its pending acquisition of Lehan's Medical Equipment, such as expected purchase price, contingent payments, closing date, funding sources, and anticipated synergies and other benefits are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the 'SEC') available on the SEC's website at including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law. For further information, please contact: Investor Relationsir@ Tripp SullivanSCR Partners, LLC615-942-7077 Trae FitzgeraldChief Financial OfficerViemed Healthcare, Inc.337-504-3802
Yahoo
21 hours ago
- Yahoo
Starbucks Tinkers With Pricing To Hold Ground In China: Report
Starbucks Corp. (NASDAQ:SBUX) will reportedly cut prices on select iced beverages in China by an average of 5 yuan (approximately 70 cents), the company announced on Monday. The move comes amid rising competition and more cautious consumer behavior in the world's second-largest economy. According to Reuters, Starbucks shared in a post on its Weixin social media account that it will begin reducing prices on dozens of beverages, including non-coffee items and Frappuccinos, starting Tuesday. The price cuts are part of an effort to make its menu more 'accessible,' with some drinks set to be priced as low as 23 yuan, or about $ to Reuters, China is Starbucks' second-largest market after the United States. Still, the coffee giant is facing increasing pressure from local competitors and a slowing economy. A source familiar with the matter told Reuters that Starbucks' pricing strategy is not a reaction to competitive pressure but a move aimed at attracting more afternoon customers. Despite previously stating it would not engage in a price war, Starbucks has introduced smaller drink sizes and issued coupons to appeal to a broader consumer base. In late May, the company reportedly explored a potential stake sale in its China business, seeking a valuation of several billion dollars. Starbucks approached tech firms and private equity groups to solicit feedback on its operations and expansion strategy. The initiative came as local rival Luckin Coffee (OTC:LKNCY) surpassed Starbucks in quarterly China revenue. Despite mounting challenges, Starbucks reiterated its commitment to long-term growth in the Chinese market. Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory. Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Starbucks, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Starbucks, the 200-day moving average sits at $95.71, according to Benzinga Pro, which is above the current price of $89.64. For more on charts and trend lines, see a description here. Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable. Price Action: SBUX shares are trading lower by 0.40% to $89.28 premarket at last check Monday. Read Next:Photo by Ned Snowman via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? STARBUCKS (SBUX): Free Stock Analysis Report This article Starbucks Tinkers With Pricing To Hold Ground In China: Report originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
